BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29898687)

  • 1. PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.
    Bertolini G; Bergamaschi L; Ferrari A; Renne SL; Collini P; Gardelli C; Barisella M; Centonze G; Chiaravalli S; Paolino C; Milione M; Massimino M; Casanova M; Gasparini P
    BMC Cancer; 2018 Jun; 18(1):652. PubMed ID: 29898687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PD-L1/PD-1 axis expression on tumor-infiltrating immune cells and tumor cells in pediatric rhabdomyosarcoma.
    Gabrych A; Pęksa R; Kunc M; Krawczyk M; Izycka-Swieszewska E; Biernat W; Bień E
    Pathol Res Pract; 2019 Dec; 215(12):152700. PubMed ID: 31704149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune contexture of paediatric cancers.
    Thakur MD; Franz CJ; Brennan L; Brouwer-Visser J; Tam R; Korski K; Koeppen H; Ziai J; Babitzki G; Ranchere-Vince D; Vasiljevic A; Dijoud F; Marec-Bérard P; Rochet I; Cannarile MA; Marabelle A
    Eur J Cancer; 2022 Jul; 170():179-193. PubMed ID: 35660252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
    Torabi A; Amaya CN; Wians FH; Bryan BA
    Pathology; 2017 Aug; 49(5):506-513. PubMed ID: 28688724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.
    Shurell E; Singh AS; Crompton JG; Jensen S; Li Y; Dry S; Nelson S; Chmielowski B; Bernthal N; Federman N; Tumeh P; Eilber FC
    Oncotarget; 2016 Sep; 7(39):64300-64308. PubMed ID: 27588404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
    Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
    Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
    Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
    Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
    Tsao MS; Le Teuff G; Shepherd FA; Landais C; Hainaut P; Filipits M; Pirker R; Le Chevalier T; Graziano S; Kratze R; Soria JC; Pignon JP; Seymour L; Brambilla E
    Ann Oncol; 2017 Apr; 28(4):882-889. PubMed ID: 28137741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
    Folpe AL; McKenney JK; Bridge JA; Weiss SW
    Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression in inflammatory myofibroblastic tumors.
    Cottrell TR; Duong AT; Gocke CD; Xu H; Ogurtsova A; Taube JM; Belchis DA
    Mod Pathol; 2018 Jul; 31(7):1155-1163. PubMed ID: 29449680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROGNOSTIC IMPLICATIONS OF PD-L1 EXPRESSION AND LOSS OF PTEN IN PATIENTS WITH RHABDOMYOSARCOMA, EWING'S SARCOMA AND OSTEOSARCOMA.
    Abd Elmoneim HM; Huwait HF; Nafady-Hego H; Mohamed FA
    Exp Oncol; 2023 Dec; 45(3):337-350. PubMed ID: 38186021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
    D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
    Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
    Kösemehmetoğlu K; Özoğul E; Babaoğlu B; Tezel GG; Gedikoğlu G
    Turk Patoloji Derg; 2017; 1(1):192-197. PubMed ID: 28832074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1
    Ilie M; Falk AT; Butori C; Chamorey E; Bonnetaud C; Long E; Lassalle S; Zahaf K; Vénissac N; Mouroux J; Cohen C; Brambilla E; Marquette CH; Hofman V; Hofman P
    Mod Pathol; 2016 Dec; 29(12):1552-1564. PubMed ID: 27562497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.
    Huang RSP; Haberberger J; Severson E; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Williams E; Elvin J; Vergilio JA; Killian JK; Lin DI; Tse J; Hiemenz M; Owens C; Danziger N; Hegde PS; Venstrom J; Alexander B; Ross JS; Ramkissoon SH
    Mod Pathol; 2021 Feb; 34(2):252-263. PubMed ID: 32884129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.
    He M; Abro B; Kaushal M; Chen L; Chen T; Gondim M; Yan W; Neidich J; Dehner LP; Pfeifer JD
    Hum Pathol; 2020 Jun; 100():15-23. PubMed ID: 32387103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
    Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
    Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Programmed Cell Death-L1 (PD-L1) Protein and Mismatch Repair Mutations in Orbital Tumours-a Pilot Study.
    AlSemari MA; Strianese D; Abu Safieh L; Al Hussain H; Abedalthagafi M; Edward DP
    Eur J Ophthalmol; 2022 Sep; 32(5):3097-3102. PubMed ID: 34931541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).
    Machado I; López-Guerrero JA; Scotlandi K; Picci P; Llombart-Bosch A
    Virchows Arch; 2018 May; 472(5):815-824. PubMed ID: 29445891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.
    Lee LH; Cavalcanti MS; Segal NH; Hechtman JF; Weiser MR; Smith JJ; Garcia-Aguilar J; Sadot E; Ntiamoah P; Markowitz AJ; Shike M; Stadler ZK; Vakiani E; Klimstra DS; Shia J
    Mod Pathol; 2016 Nov; 29(11):1433-1442. PubMed ID: 27443512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.